帕妥珠单抗
曲妥珠单抗
乳腺癌
医学
肿瘤科
内科学
单克隆抗体
紫杉烷
癌症
人表皮生长因子受体2
抗体
免疫学
作者
Jack P. Gleeson,Niamh M. Keegan,Patrick G. Morris
标识
DOI:10.1080/14712598.2018.1410132
摘要
Introduction: The monoclonal antibody trastuzumab has improved the median disease free and overall survival of patients with early stage breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). Despite this advance, some patients experience cancer relapse and novel approaches are always needed. One such advance is the monoclonal antibody pertuzumab, which prevents dimerisation between members of the HER family of transmembrane glycoprotein receptors.Areas covered: In this review, the authors analyse recent research which has focused on the development of new HER2 targeting agents for HER2-positive breast cancer, particularly pertuzumab, and its addition to trastuzumab and taxanes.Expert opinion: Pertuzumab has significantly improved disease control in patients with advanced HER2 positive breast cancer when added to chemotherapy and trastuzumab. Although pertuzumab has also increased response rates in the preoperative setting, this has not yet translated into increased overall survival. The authors believe that future research should focus on improvements in novel biomarkers to select patients for new treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI